89421-95-4

Basic information

• Product Name: CYCLOBUTANECARBONYL CHLORIDE,1-(4-CHLOROPHENYL)-
• Synonyms: CYCLOBUTANECARBONYL CHLORIDE,1-(4-CHLOROPHENYL)-;1-(4-Chlorophenyl)cyclobutanecarbonyl chloride
• CAS NO: 89421-95-4
• Molecular Formula: C₁₁H₁₀Cl₂O
• Molecular Weight: 229.11
• Mol File: 89421-95-4.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CYCLOBUTANECARBONYL CHLORIDE,1-(4-CHLOROPHENYL)-(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOBUTANECARBONYL CHLORIDE,1-(4-CHLOROPHENYL)-(89421-95-4)
• EPA Substance Registry System: CYCLOBUTANECARBONYL CHLORIDE,1-(4-CHLOROPHENYL)-(89421-95-4)

Safety Data

• Hazardous Substances Data: 89421-95-4(Hazardous Substances Data)

Upstream product

• 50921-39-6 1-(4-chlorophenyl)cyclobutane-1-carboxylic acid 

Downstream Products

• 404589-70-4 2-chloro-1-[1-(4-chloro-phenyl)-cyclobutyl]-ethanone 
• 404893-32-9 (R)-1-[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-piperidine-3-carboxylic acid ethyl ester 
• 1309195-50-3 1-(1-(4-chlorophenyl)cyclobutyl)-2-diazoethanone 
• 1309192-26-4 2-[1-(4-chlorophenyl)cyclobutyl]-N-[1-oxo-4-(trifluoromethyl)phthalazin-2(1H)-yl]acetamide 

Relevant articles and documents

Amine derivatives

The present invention relates to Kv1.3 potassium channel blockers of Formula (I) and their use in the treatment of autoimmune and inflammatory diseases.

POTASSIUM CHANNEL MODULATORS

Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring Z1, R1, p, R3, and R4 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.